MicroRNAs as novel biomarkers in colorectal cancer

Frontiers in Genetics

Volumn 3, Issue OCT, 2012, Pages

  Hrašovec, Sonja ^a   Glavač, Damjan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Colorectal cancer; DNA methylation; Microsatellite instability; MiRNAs

Indexed keywords

EID: 84874216566     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00180     Document Type: Article

References (64)

1. Akao, Y., Nakagawa, Y., and Naoe, T. (2006a). Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 29, 903-906.
2. Akao, Y., Nakagawa, Y., and Naoe, T. (2006b). MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol. Rep. 16,845-850.
3. Asangani, I. A., Rasheed, S. A., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., and Allgayer, H. (2008). MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27, 2128-2136.
4. Balaguer, F., Moreira, L., Lozano, J. J., Link, A., Ramirez, G., Shen, Y., Cuatrecasas, M., Arnold, M., Meltzer, S. J., Syngal, S., Stoffel, E., Jover, R., Llor, X., Castells, A., Boland, C. R., Gironella, M., and Goel, A. (2011). Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res. 17, 6239-6249.
5. Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman-Gomez, J., Prosper, F., and Garcia-Foncillas, J. (2009). Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 125, 2737-2743.
6. Bandrés, E., Cubedo, E., Agirre, X., Malumbres, R., Zárate, R., Ramirez, N., Abajo, A., Navarro, A., Moreno, I., Monzó, M., and García-Foncillas, J. (2006). Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 5, 29.
7. Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, andfunction. Cell 116,281-297.
8. Bartels, C. L., and Tsongalis, G. J. (2009). MicroRNAs: novel biomark-ers for human cancer. Clin. Chem. 55,623-631.
9. Bartels, C. L., and Tsongalis, G. J. (2010). MicroRNAs: novel biomark-ers for human cancer. Ann. Biol. Clin. (Paris) 68,263-272.
10. Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., and Brabletz, T. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582-589.
11. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., and Croce, C. M. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 15524-15529.
12. Chen, D. T., Hernandez, J. M., Shibata, D., McCarthy, S. M., Humphries, L. A., Clark, W., Elahi, A., Gruidl, M., Coppola, D., and Yeat-man, T. (2012a). Complementary strand microRNAs mediate acquisition of metastatic potential in colonic adenocarcinoma. J. Gas-trointest Surg. 16, 905-912.
13. Chen, M. L., Liang, L. S., and Wang, X. K. (2012b). miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin. Exp. Metastasis 29, 457-469.
14. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., Li, Q., Li, X., Wang, W., Zhang, Y., Wang, J., Jiang, X., Xiang, Y., Xu, C., Zheng, P., Zhang, J., Li, R., Zhang, H., Shang, X., Gong, T., Ning, G., Wang, J., Zen, K., Zhang, J., and Zhang, C. Y (2008). Characterization of microRNAs in serum: a novel class of biomarkersfor diagnosis of cancer and other diseases. Cell Res. 18, 997-1006.
15. Chen, X., Guo, X., Zhang, H., Xiang, Y., Chen, J., Yin, Y., Cai, X., Wang, K., Wang, G., Ba, Y., Zhu, L., Wang, J., Yang, R., Zhang, Y., Ren, Z., Zen, K., Zhang, J., and Zhang, C. Y (2009). Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28,1385-1392.
16. Cheng, H., Zhang, L., Cogdell, D. E., Zheng, H., Schetter, A. J., Nyk-ter, M., Harris, C. C., Chen, K., Hamilton, S. R., and Zhang, W. (2011). Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis. PLoS ONE 6, e 17745. doi:10.1371/journal.pone.0017745
17. Cunningham, D., Atkin, W., Lenz, H. J., Lynch, H. T., Minsky, B., Nordlinger, B., and Starling, N. (2010). Colorectal cancer. Lancet 375, 1030-1047.
18. Cunningham, J. M., Christensen, E. R., Tester, D. J., Kim, C. Y., Roche, P. C., Burgart, L. J., and Thibodeau, S. N. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58, 3455-3460.
19. De Roock, W., Jonker, D. J., Di Nicolan-tonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frat-tini, M., Piessevaux, H., Van Cutsem, E., O'Callaghan, C. J., Khambata-Ford, S., Zalcberg, J. R., Simes, J., Karapetis, C. S., Bardelli, A., and Tej-par, S. (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304,1812-1820.
20. Earle, J. S., Luthra, R., Romans, A., Abraham, R., Ensor, J., Yao, H., and Hamilton, S. R. (2010). Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn. 12, 433-440.
21. Fazi, F., and Nervi, C. (2008). MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc. Res. 79, 553-561.
22. Grady, W M., Parkin, R. K., Mitchell, P. S., Lee, J. H., Kim, Y H., Tsuchiya, K. D., Washington, M. K., Paraskeva, C., Willson, J. K., Kaz, A. M., Kroh, E. M., Allen, A., Fritz, B. R., Markowitz, S. D., and Tewari, M. (2008). Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27, 3880-3888.
23. Han, H. B., Gu, J., Zuo, H. J., Chen, Z. G., Zhao, W., Li, M., Ji, D. B., Lu, Y. Y., and Zhang, Z. Q. (2012). Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J. Pathol. 226, 544-555.
24. Han, L., Witmer, P. D., Casey, E., Valle, D., and Sukumar, S. (2007). DNA methylation regulates MicroRNA expression. Cancer Biol. Ther. 6, 1284-1288.
25. He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., and Hammond, S. M. (2005). A microRNA polycistron as a potential human oncogene. Nature 435, 828-833.
26. Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., and Du, X. (2009). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127, 118-126.
27. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
28. Kalimutho, M., Di Cecilia, S., Del Vec-chio Blanco, G., Roviello, F., Sileri, P., Cretella, M., Formosa, A., Corso, G., Marrelli, D., Pallone, F., Federici, G., and Bernardini, S. (2011). Epi-genetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br. J. Cancer 104, 1770-1778.
29. Kanaan, Z., Rai, S. N., Eichenberger, M. R., Roberts, H., Keskey, B., Pan, J., and Galandiuk, S. (2012). Plasma MiR-21: a potential diagnostic marker of colorectal cancer. Ann. Surg. 256, 544-551.
30. Kuhn, D. E., Martin, M. M., Feldman, D. S., Terry, A. V. Jr., Nuovo, G. J., and Elton, T.S. (2008). Experimental validation of miRNA targets. Methods 44,47-54.
31. Lanza, G., Ferracin, M., Gafà, R., Veronese, A., Spizzo, R., Pichiorri, F., Liu, C. G., Calin, G. A., Croce, C. M., and Negrini, M. (2007). mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 6, 54.
32. Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., and Johnson, J. M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769-773.
33. Lindow, M., and Gorodkin, J. (2007). Principles and limitations of computational microRNA gene and target finding. DNA Cell Biol. 26, 339-351.
34. Link, A., Balaguer, F., Shen, Y., Nagasaka, T., Lozano, J. J., Boland, C. R., and Goel, A. (2010). Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 19, 1766-1774.
35. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., Downing, J. R., Jacks, T., Horvitz, H. R., and Golub, T. R. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
36. Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., Gallagher, W. M., Eccles, S. A., Croce, C. M.,andEsteller,M. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U.S.A. 105, 13556-13561.
37. Mekenkamp, L. J., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Borger, E., Teerenstra, S., Kamping, E., Verwiel, E., Koopman, M., Meijer, G. A., van Krieken, H. J., Kuiper, R., Punt, C. J., Nagtegaal, I. D., and van Vliet, S. (2012). Beyond KRAS mutation status: influence of KRAS copynumber status and microRNAs on clinical outcome to cetuximab in metasta-tic colorectal cancer patients. BMC Cancer 12, 292. doi:10.1186/1471-2407-12-292
38. Michael, M. Z., O'Connor, S. M., van Holst Pellekaan, N. G., Young, G. P., and James, R. J. (2003). Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1,882-891.
39. Mirnezami, A. H., Pickard, K., Zhang, L., Primrose, J. N., and Packham, G. (2009). MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur. J. Surg. Oncol. 35, 339-347.
40. Motoyama, K., Inoue, H., Takatsuno, Y., Tanaka, F., Mimori, K., Uetake, H., Sugihara, K., and Mori, M. (2009). Over- and under-expressed microRNAs in human colorectal cancer. Int. I Oncol. 34, 1069-1075.
41. Ng, E. K., Chong, W. W., Jin, H., Lam, E. K., Shin, Y., Yu, J., Poon, T. C., Ng, S. S., and Sung, J. J. (2008). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal screening. Gut 58, 1357-1381.
42. Ng, E. K., Tsang, W. P., Ng, S. S., Jin, H. C., Yu, J., Li, J. J., Röcken, C., Ebert, M. P., Kwok, T. T., and Sung, . J. (2009). MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 101, 699-706
43. Oberg, A. L., French, A. J., Sarver, A. L., Subramanian, S., Morlan, B. W., Riska, S. M., Borralho, P. M., Cunningham, J. M., Board-man, L. A., Wang, L., Smyrk, T. C., Asmann, Y., Steer, C. J., and Thibodeau, S. N. (2011). miRNA expression in colon polyps pro vides evidence for a multihit model of colon cancer. PLoS ONE 6, e20465. doi:10.1371/journal.pone. 0020465
44. Pu, X. X., Huang, G. L., Guo, H. Q., Guo, C. C., Li, H., Ye, S., Ling, S., Jiang, L., Tian, Y., and Lin, T. Y (2010). Ciru-clating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorec tal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 25,1674-1680.
45. Saito, Y., Suzuki, H., and Hibi, T. (2009). The role of microRNAs in gastrointestinal cancers. J. Gastroenterol. 44(Suppl.19), 18-22.
46. Schepeler, T., Reinert, J. T., Ostenfeld, M. S., Christensen, L. L., Silahtaroglu, A. N., Dyrskjøt, L., Wiuf, C, S0rensen, F. J., Kruhøffer, M., Laurberg, S., Kauppinen, S., Ørntoft, T. F., and Andersen, C. L. (2008). Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68, 6416-6424.
47. Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanai-hara, N., Yuen, S. T., Chan, T. L., Kwong, D. L., Au, G. K., Liu, C. G., Calin, G. A., Croce, C. M., and Harris, C. C. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425-436.
48. Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., Hernandez, N. S., Chen, X., Ahmed, S., Kon-ishi, K., Hamilton, S. R., and Issa, J. P. (2007). Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 18654-18659.
49. Slaby, O., Svoboda, M., Fabian, P., Smerdova, T., Knoflickova, D., Bed-narikova, M., Nenutil, R., and Vyzula,R. (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopatho-logic features of colorectal cancer. Oncology 72, 397-402.
50. Slaby, O., Svoboda, M., Michalek, J., and Vyzula, R. (2009). MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer 8, 102.
51. Slattery, M. L., Wolff, E., Hoffman, M. D., Pellatt, D. F., Milash, B., and Wolff, R.K. (2011). MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 50,196-206.
52. Torrisani, J., Laurie, P., Louis, B., and Pierre, C. (2007). Enjoy the silence: the story of let-7 MicroRNA and cancer. Curr. Genomics 8, 229-233.
53. Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. (1999). CpG island methy-lator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 96, 8681-8686.
54. Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., and Tokino, T. (2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 68, 4123-4132.
55. Valeri, N., Croce, C. M., and Fabbri, M. (2009). Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics 6, 195-204.
56. Valeri, N., Gasparini, P., Braconi, C., Paone, A., Lovat, F., Fabbri, M., Sumani, K. M., Alder, H., Amadori, D., Patel, T., Nuovo, G. J., Fishel, R., and Croce, C. M. (2010a). MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. U.S.A. 107,21098-21103.
57. Valeri, N., Gasparini, P., Fabbri, M., Braconi, C., Veronese, A., Lovat, F., Adair, B., Vannini, I., Fanini, F., Bot-toni, A., Costinean, S., Sandhu, S. K., Nuovo, G. J., Alder, H., Gafa, R., Calore, F., Ferracin, M., Lanza, G., Volinia, S., Negrini, M., McIl-hatton, M. A., Amadori, D., Fishel, R., and Croce, C. M. (2010b). Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. U.S.A. 107, 6982-6987.
58. Vilar, E., Tabernero, J., and Gruber, S. B. (2011). Micromanaging the classification of colon cancer: the role of the microRNAome. Clin. Cancer Res. 17, 7207-7209.
59. Wang, C.J., Zhou, Z.G., Wang, L., Yang, L., Zhou, B., Gu, J., Chen, H. Y., and Sun, X. F. (2009). Clinicopatho-logical significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis. Markers 26, 27-34.
60. Wang, F., Zhang, P., Ma, Y., Yang, J., Moyer, M. P., Shi, C., Peng, J., and Qin, H. (2011a). NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. Cancer Lett. 314,223-231.
61. Wang, H., Wu, J., Meng, X., Ying, X., Zuo, Y., Liu, R., Pan, Z., Kang, T., and Huang, W. (2011b). MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 32, 1033-1042.
62. Williams, A. E. (2008). Functional aspects of animal microRNAs. Cell. Mol. Life Sci. 65, 545-562.
63. Yan, H., Choi, A. J., Lee, B. H., and Ting, A. H. (2011). Identification and functional analysis of epigeneti-cally silenced microRNAs in colorectal cancer cells. PLoS ONE 6, e20628. doi:10.1371/journal.pone.0020628
64. Zarate, R., Boni, V., Bandres, E., and Garcia-Foncillas, J. (2012). MiRNAs and LincRNAs: could they be considered as biomarkers in colorectal cancer? Int. J. Mol. Sci. 13, 840-865.